Application of shikimic acid as in-vivo synergist of vancomycin for treating methicillin-resistant staphylococcus aureus infectious endocarditis
By combining shikimic acid and vancomycin, the problem of vancomycin's poor efficacy in the treatment of methicillin-resistant Staphylococcus aureus infectious endocarditis is solved, significantly reducing bacterial loading and inflammation Exudate production improves therapeutic effect and reduces the amount of vancomycin used.
Patent Information
- Application Number
- CN202410991568.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-22
AI Technical Summary
The existing vancomycin treatment of methicillin-resistant Staphylococcus aureus infectious endocarditis is not ideal, and has great toxic and side effects, making it difficult to effectively reduce the production of drug resistance.
The combination of shikimic acid and vancomycin was used to significantly reduce the load of bacteria in the heart, spleen and kidneys through in vivo experiments, and reduce the production of inflammatory exudates on the heart valves.
It significantly improves the antibacterial activity and therapeutic effect of vancomycin, reduces the dosage and toxic side effects of vancomycin, and provides better theoretical basis for clinical treatment and practical guidance.
Smart Images

Figure CN118986949A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of disease treatment, and more specifically, relates to the application of shikimic acid as an in vivo synergist of vancomycin in treating methicillin-resistant Staphylococcus aureus infective endocarditis. Background Art
[0002] Infective endocarditis (IE) is an endocardial infection caused by pathogenic microorganisms, which usually leads to damage to the heart valves. Although the use of antibiotics has greatly reduced the incidence of infective endocarditis, the emergence of drug-resistant strains, especially methicillin-resistant Staphylococcus aureus (MRSA), has brought great challenges to clinical treatment. MRSA is a common drug-resistant strain that occupies an important position in hospital infections due to its resistance to multiple antibiotics. Infective endocarditis caused by MRSA has a high mortality rate and complication rate, and existing treatment methods usually rely on vancomycin. However, the efficacy of vancomycin is not always ideal, and its toxic side effects also limit its application. Therefore, finding new therapeutic strategies to enhance the antibacterial effect of vancomycin and reduce its toxicity has become the focus of current research.
[0003] Shikimic acid is a natural compound found in many plants and is a precursor for the synthesis of many important biomolecules. In recent years, studies have shown that shikimic acid has significant antibacterial, anti-inflammatory and immunomodulatory effects. Its mechanism of action may involve interfering with bacterial metabolic pathways and enhancing host immune responses. However, the effect of shikimic acid alone in severe infections has not been fully determined. In antibacterial therapy, combination therapy is a common strategy aimed at enhancing antibacterial effects, reducing the development of drug resistance and reducing drug toxicity. Summary of the invention
[0004] In order to overcome the deficiencies of the prior art, the present invention aims to provide the use of shikimic acid as an in vivo synergist of vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infective endocarditis.
[0005] The purpose of the present invention is achieved through the following technical solutions:
[0006] The present invention firstly used shikimic acid for in vivo experiments, that is, shikimic acid and vancomycin were used in rat IE models. The results showed that the combination of shikimic acid and vancomycin significantly reduced the bacterial load in the heart vegetation, spleen and kidney of IE rats. The terminal bacterial load of the heart vegetation in the vancomycin monotherapy group was 9.28log 10 CFU / g; the terminal bacterial count in the kidney of the shikimic acid monotherapy group was 8.7log10 CFU / g; when the two drugs are combined, the final bacterial count of cardiac vegetation is 6.8log 10 CFU / g, and compared with the control group, the bacterial load of cardiac vegetation decreased by at least 2.5log 10 CFU / g, indicating that the combination of the two drugs has a good therapeutic effect in vivo. In rat kidney and spleen samples, the combined therapeutic effect of the two drugs is still better than that of single drugs.
[0007] Therefore, the present invention first provides the use of shikimic acid in preparing an in vivo synergist for vancomycin in treating methicillin-resistant Staphylococcus aureus infective endocarditis.
[0008] Preferably, the methicillin-resistant Staphylococcus aureus is ATCC 43300, the dosage of shikimic acid is 50-200 mg / kg, and the dosage of vancomycin is 15-20 mg / kg.
[0009] The present invention also provides the use of shikimic acid and vancomycin in combination as a drug for treating methicillin-resistant Staphylococcus aureus infective endocarditis in vivo.
[0010] In addition, both macroscopically and histologically, the combination of shikimic acid and vancomycin significantly reduced the formation of inflammatory exudates (vegetation) on rat heart valves; in addition, Gram staining results showed that the combination of shikimic acid and vancomycin significantly reduced the bacterial load in the vegetation.
[0011] Therefore, preferably, in the above application, the shikimic acid and vancomycin are used in combination to reduce the generation of inflammatory exudates on rat heart valves.
[0012] Compared with the prior art, the present invention has the following beneficial effects:
[0013] The present invention accidentally discovered that shikimic acid and vancomycin have no synergistic effect when used together in vitro, but can significantly reduce the bacterial load in vegetation in vivo and significantly reduce the generation of inflammatory exudate (vegetation) on rat heart valves. Therefore, shikimic acid is used as an in vivo synergist of vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infective endocarditis, thereby improving the antibacterial activity of vancomycin, improving the therapeutic effect, reducing the dose of vancomycin required for treatment, and reducing the toxic side effects of vancomycin.
[0014] The results of this study will provide new theoretical basis and practical guidance for the clinical treatment of MRSA infective endocarditis, and have important scientific significance and application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1The results of the chessboard method for the combination of shikimic acid with tigecycline (TIG), tobramycin (TOB), ciprofloxacin (CIP), levofloxacin (LEV), tetracycline (TET), and gentamicin (GEN);
[0016] Figure 2 The results of the chessboard method for the combination of shikimic acid with vancomycin (VAN), linezolid (LZD), teicoplanin (TEI), and ampicillin (AMP);
[0017] Figure 3 Figure 1 is a diagram of the rat modeling process;
[0018] Figure 4 is the bacterial load in cardiac vegetation, spleen and kidney of rats with infective endocarditis. Each point represents the bacterial load in the target tissue of one rat in the endocarditis model (n=6);
[0019] Figure 5 Actual anatomical diagram and tissue staining of IE rat heart tissue. DETAILED DESCRIPTION
[0020] In order to better illustrate the purpose, technical scheme and advantages of the present invention, the present invention will be further described below in conjunction with specific drawings and embodiments. In the embodiments, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all commercially available unless otherwise specified.
[0021] Example 1 Determination of MIC of shikimic acid and different antibiotics against strain ATCC43300
[0022] 1. Experimental materials:
[0023] The autoclaved CAMH broth was cooled for later use. MRSA standard strain ATCC43300 (laboratory collection). Tigecycline (TIG), tobramycin (TOB), ciprofloxacin (CIP), levofloxacin (LEV), tetracycline (TET), gentamicin (GEN), vancomycin (VAN), linezolid (LZD), teicoplanin (TEI), ampicillin (AMP), the above drugs were prepared to a concentration of 5120 μg / mL, and the shikimic acid stock solution was prepared to 100 mg / mL and stored at -20°C.
[0024] 2. Preparation before the test: Cultivate MRSA strain ATCC43300 on brain heart infusion medium to an appropriate size.
[0025] 3. Experimental evaluation of bactericidal effects of shikimic acid and different antibiotics:
[0026] (1) The test strain was transferred to a 50 mL sterile centrifuge tube containing 10 mL CAMH broth, and incubated at 180 rpm in a 37°C shaker until the logarithmic growth phase. The centrifuge tube was removed; the MRSA cells were collected by centrifugation at 3000 rpm for 10 min, and then washed twice with PBS solution and resuspended. The centrifuged and resuspended bacterial solution was adjusted to OD using a spectrophotometer. 600 =0.5, i.e. 1 to 5×10 8 CFU / mL;
[0027] (2) Use CAMH broth to dilute the incubated 43000 strain 100 times to about 1-5×10 6 CFU / mL, reserve;
[0028] (3) Take a sterile 96-well plate, add 180 μL CAMH broth medium to well 1, and add 100 μL CAMH broth medium to wells 2-11;
[0029] (4) Add 20 μL of shikimic acid or antibiotics to the first well, pipette and mix well, then pipette 100 μL into the second well, and so on. Pipet 100 μL into the tenth well and discard it;
[0030] (5) Add 100 μL of diluted bacterial solution to wells 1 to 10 and 200 μL of CAMH broth to well 12;
[0031] (6) Repeat steps (3) to (5) three times in parallel;
[0032] (7) Place the sample in a 37°C incubator for 18-24 h and determine the MIC value based on the turbidity.
[0033] The minimum inhibitory concentrations of shikimic acid and different antibiotics against MRSA strain ATCC43300 are shown in Table 1.
[0034] Table 1 MIC values of shikimic acid and different antibiotics against ATCC43300 strain
[0035]
[0036]
[0037] Example 2 Chessboard method of shikimic acid and different antibiotics against MRSA strain ATCC43000
[0038] 1. Experimental materials:
[0039] The autoclaved MH broth was cooled for later use. MRSA standard strain ATCC43300 (laboratory collection). Tigecycline (TIG), tobramycin (TOB), ciprofloxacin (CIP), levofloxacin (LEV), tetracycline (TET), gentamicin (GEN), vancomycin (VAN), linezolid (LZD), teicoplanin (TEI), ampicillin (AMP), the above drugs were prepared to a concentration of 5120 μg / mL, and the shikimic acid stock solution was prepared to 100 mg / mL and stored at -20°C.
[0040] 2. Preparation before the test: Cultivate MRSA strain ATCC43300 on brain heart infusion medium to an appropriate size.
[0041] 3. Chessboard experiment of shikimic acid and different antibiotics against MRSA strains
[0042] (1) The test strain was transferred to a 50 mL sterile centrifuge tube containing 10 mL MH broth, and incubated at 180 rpm in a 37°C shaker until the logarithmic growth phase. The centrifuge tube was removed; the MRSA cells were collected by centrifugation at 3000 rpm for 10 min, and then washed twice with PBS solution and resuspended. The centrifuged and resuspended bacterial solution was adjusted to OD using a spectrophotometer. 600 =0.5, i.e. 1 to 5×10 8 CFU / mL;
[0043] (2) Use MH broth to dilute the incubated 43000 strain 100 times to about 1-5×10 6 CFU / mL, reserve;
[0044] (3) Take a 96-well plate and add 50 μL of fresh sterile MH broth in columns 1 to 8. Use antibiotic as drug A. Add 50 μL of antibiotic with 16 times the MIC value for the test strain to wells 1 to 8 in row A. Mix by pipetting. Pipet 50 μL to row B, then dilute to row G in multiple proportions. Finally, take 50 μL of the solution and discard it.
[0045] (4) Shikimic acid was used as drug B. Shikimic acid was diluted in series from 8 times the MIC concentration to 1 / 8 times the MIC concentration of the test strain outside the 96-well plate. 50 μL of shikimic acid at 8 times the MIC concentration was added to the first column, 50 μL of shikimic acid at 4 times the MIC was added to the second column, and so on until the seventh column, where 1 / 8 times the MIC of shikimic acid was added. Finally, 50 μL of broth was added to the last column.
[0046] (5) Add 100 μL of the diluted bacterial solution to each well and incubate at 37°C for 18–22 h. Repeat the experiment three times.
[0047] (6) Results presentation: The results of the chessboard method were presented in a heat map using GraphPadPrism software and the FIC value after the two drugs were used together was calculated according to the following formula: Synergistic effect means FICI ≤ 0.5;
[0048] FIC=MIC A药联合 / MIC A药单用 +MIC B药联合 / MIC B药单用
[0049] The results are as follows Figure 1 , 2 :When shikimic acid was used in combination with ampicillin (AMP), it showed a synergistic effect. However, when shikimic acid was used in combination with other antibiotics, the FIC was greater than 0.5, indicating no synergistic effect.
[0050] It is clear that the combination of shikimic acid and vancomycin in vitro has no synergistic effect on the standard strain of MRSA ATCC43300.
[0051] Example 3 Pharmacodynamic evaluation of shikimic acid combined with vancomycin in a rat infective endometritis model
[0052] 1. Rat MRSA-induced infective endocarditis model
[0053] (1) Rats were anesthetized by intraperitoneal injection of 20 mg / kg of Zota and fixed on the operating table. The skin of the rat's neck area from the chin to slightly below the sternum was prepared and disinfected with 75% alcohol. A small incision was made with a scalpel on the right side of the center of the rat's neck to expose the surgical site. The subcutaneous tissue and muscle were carefully separated with forceps. The right common carotid artery was separated and the distal end was ligated with surgical sutures. The proximal end was clamped with an artery clamp, and a surgical suture was prepared to tie a small knot at the proximal end (not ligated) to prepare for rapid ligation in the subsequent process to reduce the amount of bleeding in the rat. A small oblique incision was made in the right common carotid artery with ophthalmic surgical scissors, and a PE-10 catheter was inserted. The artery clamp was removed and the catheter was slowly pushed in until resistance was encountered. After resistance was encountered, the catheter was slightly retracted. The catheter insertion distance was about 4 to 4.5 cm. The proximal end was ligated and the end of the catheter was sealed. After the catheter was successfully inserted, it can be seen that the catheter has a strong pulsation with the heart, indicating that the catheter has entered the left ventricular cavity. Finally, the surgical incision was sutured, and the rat was placed on a heating pad to maintain body temperature and wait for recovery after surgery. After recovery, the rat was returned to the cage for feeding and bacterial infection was performed 24 hours later.
[0054] (2) Bacterial infection, animal grouping and drug administration
[0055] ATCC 43300 strain was cultured in MH medium at 37°C for 24 h and diluted to about 2 × 10 5CFU / mL was injected into the tail vein to infect model rats (0.5mL / rat). After 24h of infection, the surviving rats were randomly divided into a model group (blank control group), a shikimic acid monotherapy group, a vancomycin monotherapy group, and a shikimic acid and vancomycin combination group. The treatment cycle was three days, and the dosages were vancomycin treatment group (15mg / kg, 2 times / day, intravenous injection); shikimic acid treatment group (100mg / kg, 2 times / day, gavage); shikimic acid and vancomycin treatment group (vancomycin 15mg / kg, intravenous injection, 2 times / day; shikimic acid 100mg / kg, gavage, 2 times / day), and the control group was given the same volume of normal saline.
[0056] (3) Cardiac vegetation examination and tissue colony count
[0057] Tissue colony counts and vegetation examinations were performed 24 hours after the last administration. The specific process was as follows: the animals were killed by intraperitoneal injection of an overdose of sodium pentobarbital solution, the abdominal and thoracic cavities of the animals were wiped with 75% alcohol, a V-shaped opening was cut in the abdomen with surgical scissors, and the spleen and kidneys of the animals were removed. The thoracic cavity was then opened, the right common carotid artery was carefully separated, the position of the catheter was observed and it was confirmed whether the catheter was inserted into the heart, the heart was removed along the direction of the catheter, the heart was cut open along the catheter, and the formation of vegetation was closely observed in the left ventricular cavity, at the valve and around the catheter. All those whose catheters were not in the heart were eliminated. The vegetation (including mural vegetation) was picked up, and the weight of each tissue and vegetation was weighed under sterile conditions. The collected spleen, kidney and heart vegetation were crushed and diluted in multiples to obtain the residual bacterial count of MRSA in the treated tissues. (Log 10 cfu / g).
[0058] (4) HE and Gram staining of heart
[0059] The complete hearts of rats in each group were taken and perfused with saline to remove the blood in the heart. After the perfusion was completed, the excess saline was wiped off with sterile gauze and placed in paraformaldehyde tissue fixative. The heart samples were transferred to the company for tissue staining.
[0060] (5) Statistical processing
[0061] GraphPad Prism software was used to analyze the results, and one-way analysis of variance was used to compare the significance of the data among the groups. The test results were judged, and P < 0.05 was considered to be significantly different, with *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001.
[0062] The results are as follows Figure 4As shown in the figure, the combination of shikimic acid and vancomycin significantly reduced the bacterial load in the heart vegetation, spleen and kidney of IE rats. The terminal bacterial load in the heart vegetation of the vancomycin monotherapy group was 9.28log 10 CFU / g; the terminal bacterial count in the kidney of the shikimic acid monotherapy group was 8.7log 10 CFU / g; when the two drugs are combined, the final bacterial count of cardiac vegetation is 6.8log 10 CFU / g, and compared with the control group, the bacterial load of cardiac vegetation decreased by at least 2.5log 10 CFU / g, indicating that the combination of the two drugs has a good therapeutic effect in vivo. In rat kidney and spleen samples, the combined therapeutic effect of the two drugs is still better than that of single drugs.
[0063] In addition, both from the macroscopic and histological perspectives, the combination of shikimic acid and vancomycin significantly reduced the formation of inflammatory exudates (vegetation) on the heart valves of rats (indicated by the yellow box in the HE staining image); in addition, Gram staining ( Figure 5 )The results showed that the combination of shikimic acid and vancomycin significantly reduced the bacterial load in the vegetation.
[0064] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. Application of shikimic acid in the preparation of an in vivo synergist of vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infective endocarditis.
2. The use according to claim 1, It is characterized in that The methicillin-resistant Staphylococcus aureus is ATCC43300, the dosage of shikimic acid is 50-200 mg / kg, and the dosage of vancomycin is 15-20 mg / kg.
3. Application of shikimic acid and vancomycin in combination as a drug for the in vivo treatment of methicillin-resistant Staphylococcus aureus infective endocarditis.
4. The use according to any one of claims 1 to 3, It is characterized in that The combination of shikimic acid and vancomycin reduces the production of inflammatory exudate on rat heart valves.
Citation Information
Cited By
Application of shikimic acid in preparation of synthetic antibacterial preparation for inhibiting staphylococcus flavin
CN122140683A
